Biotech Values

[swampboots]

DEW: Tell me if I am wrong, but I am picking up from this stunning single case success that dozens of vascular targeting agent Bio houses (like PPHM patent house holds) perhaps have an effective vessel killer in their untested (for wet AMD application) patent inventory.
So is there spector of major dilution for eventual market share for these anti vessel destroyers which can effectively target the AMD disease? Perhaps no stand alone first to market
entity will garner huge profits for long ( on the broad applications of reconfigured vascular targeting agents)?